Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer

Pharmacological inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are now an established standard of care for patients with advanced hormone receptor-positive breast cancer. The canonical mechanism underlying CDK4/6 inhibitor activity is the suppression of phosphorylation of the retinoblastoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Watt, April C., Goel, Shom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898415/
https://www.ncbi.nlm.nih.gov/pubmed/35248122
http://dx.doi.org/10.1186/s13058-022-01510-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898415/
https://www.ncbi.nlm.nih.gov/pubmed/35248122
http://dx.doi.org/10.1186/s13058-022-01510-6

Ejemplares similares